Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Johnson David Michael reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director David Michael Johnson received an equity award rather than making an open-market trade. He was granted 57,100 restricted stock units under the company’s Non-Employee Director Compensation Program, each representing one share of common stock at no cash cost to him.
The units will vest on the earlier of June 16, 2027 or the next annual stockholder meeting, as long as he continues serving on the board through that date. Following this award, Johnson directly holds 307,521 shares of Zentalis common stock.
Skvarka Jan reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Jan Skvarka received 57,100 restricted stock units as equity compensation. The grant was made at no cash cost and will vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to continued board service. Following this award, Skvarka holds 264,254 shares/units of common stock.
Walker Luke Nathaniel reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Luke Nathaniel Walker received an equity award of 57,100 shares of common stock in the form of restricted stock units. These units were granted at no cash cost and increase his direct holdings to 201,384 shares of common stock.
The restricted stock units each represent a contingent right to receive one share of common stock. They will vest on the earlier of June 16, 2027 or the next annual meeting of stockholders, provided Walker continues to serve on the board through the vesting date. This is a compensation-related grant rather than an open-market purchase.
Kariuki Enoch reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Enoch Kariuki received an equity award in the form of restricted stock units. The grant covers 57,100 RSUs, each representing one share of common stock at no purchase price. After this award, he directly holds 194,465 shares. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, if he continues serving on the board.
Myers Scott Dunseth reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Scott Dunseth Myers received a grant of 57,100 restricted stock units (RSUs). The award was made at no cash cost and increases his direct holdings to 395,895 shares of common stock. The RSUs vest on the earlier of June 16, 2027 or the next annual stockholder meeting, subject to his continued board service.
Zentalis Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 16, 2026. A total of 49,453,766 shares were present or represented by proxy, representing approximately 69.47% of outstanding common stock as of the April 20, 2026 record date, establishing a strong quorum.
Stockholders elected David Johnson and Jan Skvarka, Ph.D., as Class III directors to serve until the 2029 Annual Meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026 and approved, on an advisory basis, the compensation of the named executive officers.
Campbell Shannon reported acquisition or exercise transactions in this Form 4 filing.
Zentalis Pharmaceuticals director Shannon Campbell received an equity grant in the form of restricted stock units. The award covers 114,200 shares of common stock at no purchase price, granted under the company’s Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, contingent on continued board service, resulting in 114,200 shares reported as directly owned after this grant.
Zentalis Pharmaceuticals, Inc. director Campbell Shannon filed an initial Form 3 insider ownership report. The excerpt shows no reported transactions, no derivative positions, and no holding entries, indicating that this filing is purely administrative disclosure of insider status without visible trading activity.
Zentalis Pharmaceuticals expanded its Board of Directors from six to seven members and appointed Shannon Campbell as a Class I director. Her term runs until the 2027 annual stockholder meeting, and she will also serve on the Board’s Compensation Committee.
Campbell will be paid under the company’s standard non-employee director program, including a $45,000 annual cash retainer for Board service and an additional $7,500 annual retainer for Compensation Committee membership. As a new director, she received 114,200 restricted stock units, calculated as 0.16% of the common shares outstanding before grant, vesting in equal installments over three years.
After six months of service, she will become eligible for an annual equity award equal to 0.08% of shares outstanding before each grant, which generally vests in full by the next annual meeting or the first anniversary of grant. All of Campbell’s director equity awards vest in full upon a change in control, subject to her continued service, and she has entered into the company’s standard indemnification agreement for directors and officers.
Zentalis Pharmaceuticals reported updated Phase 1b MUIR trial results for its investigational WEE1 inhibitor azenosertib combined with paclitaxel in platinum-resistant ovarian cancer (PROC). In 46 all-comer PROC patients across four dose cohorts, the regimen achieved a 39.1% overall response rate and 58.7% clinical benefit rate, with median duration of response of 5.6 months and median progression-free survival of 7.3 months as of the December 1, 2025 cutoff. These outcomes are described as encouraging versus historical paclitaxel monotherapy data of roughly 30% response and 4-month median progression-free survival.
At the 250 mg intermittent 5:2 azenosertib dose (12 patients), overall response rate was 50.0%, clinical benefit rate 66.7%, and median duration of response 9.2 months, supporting this as a potential optimal combination dose. Activity appeared similar in Cyclin E1‑positive and Cyclin E1‑negative tumors. The safety profile was characterized as manageable: common treatment-related adverse events included fatigue, anemia, nausea, and neutropenia, with Grade ≥3 neutropenia in 30.4% and anemia in 19.6% of patients, and one Grade 5 sepsis event considered related to azenosertib.